Pearson correlations among distress measures and WPAI impairment.

<p>Pearson correlations among distress measures and WPAI impairment.</p

Quantile regression point estimates 95% confidence intervals for absenteeism (percent of work time missed due to health) (N = 457), presenteeism (percent impairment while at work) (N = 462), and general activity impairment (N = 939).

<p>Quantile regression point estimates 95% confidence intervals for absenteeism (percent of work time missed due to health) (N = 457), presenteeism (percent impairment while at work) (N = 462), and general activity impairment (N = 939).</p

Frequencies, means and medians of characteristics for the employed group compared to the not-working group.

<p>Frequencies, means and medians of characteristics for the employed group compared to the not-working group.</p

Quantile regression point estimates and standardized estimates with 95% confidence intervals for absenteeism (percent of work time missed due to health), presenteeism (percent of impairment at work due to health), and general activity impairment (percent of activity impairment due to health).

<p>Distress variables examined individually in separate regression models.</p

Baseline characteristics for the total sample and employed subsample, stratified by illness group (IMID versus anxiety/depression).

<p>Baseline characteristics for the total sample and employed subsample, stratified by illness group (IMID versus anxiety/depression).</p

Inception characteristics of subjects in CATCH and of patients with available serial radiographs.

<p>* No significant differences identified except for anti-CCP (p<0.001); Swollen Joint Count (p<0.001), non-biologic DMARD combination therapy (p<0.01) and Steroid exposure (p = 0.003).</p><p>** Comorbidities recorded include: angina/heart attack, asthma, other heart problems, hypertension, cerebrovascular disease/accidents, anemia, bronchitis/emphysema, hypercholesterolemia, bowel disease, stomach ulcer, liver disease, kidney disease, tuberculosis, cancer, psoriasis, thyroid disease, diabetes, hepatitis, chronic infection, osteoarthritis, lupus, osteoporosis, back/spine problems, fibromyalgia, fractures, depression, mental illness, alcoholism, severe allergies, thromboembolic disease, Parkinson disease, migraines, seizures/epilepsy, gynecologic/prostate problems, HIV, herpes and/or cold sores.</p><p>*** Reported by site investigator; not from central reader</p><p>Results are reported as a Mean (SD) unless otherwise noted. RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; DAS28, disease activity score using a 28-joint count; HAQ Health Assessment Questionnaire; DMARD, disease modifying anti-rheumatic drug</p

Predicted Group Trajectories in Early Rheumatoid Arthritis based on DAS28 with 95% CI (n = 1,586).

<p>Five predicted group trajectories (solid or dashed lines) and 95% confidence interval limits (shaded) are depicted from the group-based trajectory modelling. Percentages reflect the predicted proportion of subjects in each group, which differs marginally from the actual group characterization in the dataset.</p

Cohort Derivation.

<p>Flow diagram of subjects included in the study.</p

Treatment by Trajectory Group.

<p>(A) Group Proportion on Methotrexate (≥15 mg), by Visit Month. (B) Group Proportion on Combination Methotrexate and DMARD Therapy, by Visit Month. (C) Group Proportion on Biologics, by Visit Month. (D) Group Proportion on Corticosteroids, by Visit Month.</p